The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
Open accessAbstract
Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncology and virology. However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chemical space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics. Retrospective analysis of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compounds and improve the efficiency of drug design for future projects. We present here highlights and case studies of lessons learned from discovery of bRo5 compounds. A simple multiparametric scoring function (AB-MPS) was devised that correlated preclinical PK results with cLogD, number of rotatable bonds, and number of aromatic rings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
Self-citationABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationQuantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?
Giordanetto, F., & Kihlberg, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm400887j · Cited by 563
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
Self-citationRezai, T., Yu, B., Millhauser, G. L., Jacobson, M. P., & Lokey, R. S. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0563455 · Cited by 490
Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase
Tellinghuisen, T. L., Marcotrigiano, J., & Rice, C. M. (2005) · Nature · doi:10.1038/nature03580 · Cited by 486
Schneider, N., Lowe, D. M., Sayle, R. A., Tarselli, M. A., & Landrum, G. A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00153 · Cited by 427
Villar, E. A., Beglov, D., Chennamadhavuni, S., Porco, J. A., Kozakov, D., Vajda, S., & Whitty, A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1584 · Cited by 400
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
Time-Related Differences in the Physical Property Profiles of Oral Drugs
Leeson, P. D., & Davis, A. M. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049717d · Cited by 326
Young, R. J., Green, D. V. S., Luscombe, C. N., & Hill, A. P. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.001 · Cited by 311
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 304
Self-citationHow Big Is Too Big for Cell Permeability?
Matsson, P., & Kihlberg, J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00237 · Cited by 303
Park, C.-M., Bruncko, M., Adickes, J., Bauch, J., Ding, H., Kunzer, A., Marsh, K. C., Nimmer, P., Shoemaker, A. R., Song, X., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800669s · Cited by 300
Self-citationCell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs
Whitty, A., Zhong, M., Viarengo, L., Beglov, D., Hall, D. R., & Vajda, S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.005 · Cited by 285
Meanwell, N. A. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00043 · Cited by 239
Cell-Permeable Cyclic Peptides from Synthetic Libraries Inspired by Natural Products
Hewitt, W. M., Leung, S. S. F., Pye, C. R., Ponkey, A. R., Bednarek, M., Jacobson, M. P., & Lokey, R. S. (2015) · Journal of the American Chemical Society · doi:10.1021/ja508766b · Cited by 210
Structural and conformational determinants of macrocycle cell permeability
Over, B., Matsson, P., Tyrchan, C., Artursson, P., Doak, B. C., Foley, M. A., Hilgendorf, C., Johnston, S. E., Lee, M. D., Lewis, R. J., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2203 · Cited by 209
Molecular inflation, attrition and the rule of five
Leeson, P. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.018 · Cited by 179
Wang, C. K., Northfield, S. E., Colless, B., Chaousis, S., Hamernig, I., Lohman, R.-J., Nielsen, D. S., Schroeder, C. I., Liras, S., Price, D. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417611111 · Cited by 171
Pye, C. R., Hewitt, W. M., Schwochert, J. A., Haddad, T. D., Townsend, C. E., Etienne, L., Lao, Y., Limberakis, C., Furukawa, A., Mathiowetz, A. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01483 · Cited by 163
The influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
Goetz, G. H., Philippe, L., & Shapiro, M. J. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500239m · Cited by 160
Improving on Nature: Making a Cyclic Heptapeptide Orally Bioavailable
Nielsen, D. S., Hoang, H. N., Lohman, R., Hill, T. A., Lucke, A. J., Craik, D. J., Edmonds, D. J., Griffith, D. A., Rotter, C. J., Ruggeri, R. B., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201405364 · Cited by 147
Banerjee, D., & Reddy, K. R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13514 · Cited by 141
Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules
Firth, N. C., Brown, N., & Blagg, J. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300293f · Cited by 139
Salem, A. H., Agarwal, S. K., Dunbar, M., Enschede, S. H., Humerickhouse, R. A., & Wong, S. L. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.821 · Cited by 135
Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
DeGoey, D. A., Randolph, J. T., Liu, D., Pratt, J. K., Hutchins, C. W., Donner, P., Krueger, A. C., Matulenko, M. A., Patel, S. V., Motter, C. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401398x · Cited by 131
Self-citationHigh Throughput Method for the Indirect Detection of Intramolecular Hydrogen Bonding
Goetz, G. H., Farrell, W. P., Shalaeva, M. Y., Sciabola, S., Anderson, D. P., Yan, J., Philippe, L., & Shapiro, M. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401859b · Cited by 119
Use of 3D Properties to Characterize Beyond Rule-of-5 Property Space for Passive Permeation
Guimarães, C. R. W., Mathiowetz, A. M., Shalaeva, M. Y., Goetz, G. H., & Liras, S. I. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300010y · Cited by 117
Pilot-Matias, T., Tripathi, R. L., Cohen, D. E., Gaultier, I., Dekhtyar, T., Lu, L., Reisch, T., Irvin, M., Hopkins, T., Pithawalla, R. B., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04227-14 · Cited by 117
Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA
Ascher, D. B., Wielens, J., Nero, T. L., Doughty, L., Morton, C. J., & Parker, M. W. (2014) · Scientific Reports · doi:10.1038/srep04765 · Cited by 116
Belema, M., & Meanwell, N. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500335h · Cited by 112
Predicting Drug Absorption: How Nature Made It a Difficult Problem
Burton, P. S., Goodwin, J. T., Vidmar, T. J., & Amore, B. M. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035006 · Cited by 108
Increasing small molecule drug developability in sub-optimal chemical space
Ritchie, T. J., Macdonald, S. J. F., Peace, S., Pickett, S. D., & Luscombe, C. N. (2013) · MedChemComm · doi:10.1039/c3md00003f · Cited by 100
When barriers ignore the “rule-of-five”
Krämer, S. D., Aschmann, H. E., Hatibovic, M., Hermann, K. F., Neuhaus, C. S., Brunner, C., & Belli, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.001 · Cited by 77
Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors
Belema, M., Lopez, O. D., Bender, J. A., Romine, J. L., Laurent, D. R. S., Langley, D. R., Lemm, J. A., O’Boyle, D. R., Sun, J.-H., Wang, C., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401793m · Cited by 75
Choo, E. F., Boggs, J. W., Zhu, C., Lubach, J. W., Catron, N. D., Jenkins, G. J., Souers, A. J., & Voorman, R. L. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055053 · Cited by 66
Lawitz, E., O’Riordan, W. D., Asatryan, A., Freilich, B. L., Box, T. D., Overcash, J. S., Lovell, S., Ng, T. I., Liu, W., Campbell, A. L., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02264-15 · Cited by 61
Durmuş, S., van Hoppe, S., & Schinkel, A. H. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.005 · Cited by 56
Updating molecular properties during early drug discovery
Caron, G., & Ermondi, G. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.017 · Cited by 35
Abbott Physicochemical Tiering (APT)—A unified approach to HTS triage
Cox, P. B., Gregg, R. J., & Vasudevan, A. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.047 · Cited by 31
Self-citationXiong, H., Pradhan, R. S., Nada, A., Krivoshik, A., Holen, K. D., Rhodes, J. W., Gordon, G., Humerickhouse, R. A., & Awni, W. M. (2014) · PubMed · Cited by 22
Wakenhut, F., Tran, T. D., Pickford, C., Shaw, S. M., Westby, M., Smith‐Burchnell, C., Watson, L., Paradowski, M., Milbank, J. B. J., Stonehouse, D., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201400046 · Cited by 19
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
Wendt, M. D. (2012) · Topics in medicinal chemistry · doi:10.1007/978-3-642-28965-1_7 · Cited by 18
Self-citationTanaka, Y., Kitamura, Y., Maeda, K., & Sugiyama, Y. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.005 · Cited by 10
Cited by
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Newman, D. J., & Cragg, G. M. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01285 · Cited by 7,015
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design
Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,655
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
Self-citationPROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 800
Metadata
- Authors
- DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-09-19
- Volume
- 61
- Issue
- 7
- Pages
- 2636-2651
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2756205407
- Cited by
- 378
- References
- 53
- FWCI
- 18.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.